Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Amazon Explores AI Content Marketplace With Media Publishers 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SYDNEY, Australia, Nov. 20, 2017 -- Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” or the “Company”) has announced a rebranding of the Company from Prima BioMed Ltd to Immutep Ltd (“Immutep”) following shareholder approval at its Annual General Meeting on 17 November 2017.
Following the acquisition of Immutep S.A.S (the Company’s 100% owned subsidiary in France) in December 2014 and subsequent sale under license of the Company’s former cancer vaccine CVac to Sydys Corporation, its sole focus has been on developing its portfolio of LAG-3 based immunotherapy assets.
The name Immutep has a strong association with LAG-3 and its founder, Prima’s Chief Scientific Officer and Chief Medical Officer, Dr. Frederic Triebel. Additionally, many of the Company’s clinical partner associations are with Immutep and several patents remain registered under the Immutep name.
CEO Marc Voigt said: “As the global leader in LAG-3, the name Immutep better represents our corporate identity and activities. As it is already embedded in our day to day operations, costs associated with the rebrand will be minimal so it makes both strategic and economic sense. Immutep is already associated with LAG-3 and we see this as an important step in building awareness of our market position and exciting asset portfolio.”
Subject to relevant regulatory approvals, the Company’s new ASX Code will be ‘IMM’ and its new Nasdaq code will be ‘IMMP’.
The effective date for the name change and the ticker codes on the ASX and NASDAQ will be on or around the commencement of trading on Friday, 1 December 2017.
Further shareholder information regarding the change of name can be accessed on the Company’s website www.primabiomed.com.au.
About Prima BioMed
Prima is listed on the Australian Securities Exchange and on the NASDAQ in the US.
For further information please contact:
U.S. Investors:
Jay Campbell, Vice President of Business Development and Investor Relations, Prima BioMed
+1 (917) 860-9404; [email protected]
Matthew Beck, The Trout Group LLC
+1 (646) 378-2933; [email protected]
Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; [email protected]
